These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38658299)

  • 1. The Future of Front-line Metastatic Bladder Cancer is Platinum-free.
    Young M
    Eur Urol Focus; 2024 Mar; 10(2):215-216. PubMed ID: 38658299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
    Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval.
    Zameer U; Shaikh W
    Tumori; 2024 Aug; 110(4):295-296. PubMed ID: 38142292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
    Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
    Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
    Apolo AB; Bellmunt J; Cordes L; Gupta S; Powles T; Rosenberg JE; Van Der Heijden MS
    ESMO Open; 2024 Sep; 9(9):103725. PubMed ID: 39236601
    [No Abstract]   [Full Text] [Related]  

  • 8. Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
    Vogl UM; Testi I; De Santis M
    Eur Urol Focus; 2024 Mar; 10(2):217-218. PubMed ID: 38582643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Catalano M; Santoni M; Roviello G
    Eur Urol; 2024 Sep; 86(3):283. PubMed ID: 38744633
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
    Eur Urol; 2024 Sep; 86(3):282-283. PubMed ID: 38631993
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
    Eur Urol; 2024 Sep; 86(3):280-281. PubMed ID: 38599990
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Zhu X; Koshkin VS
    Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
    Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
    Merseburger AS; Apolo AB; Chowdhury S; Hahn NM; Galsky MD; Milowsky MI; Petrylak D; Powles T; Quinn DI; Rosenberg JE; Siefker-Radtke A; Sonpavde G; Sternberg CN
    World J Urol; 2019 Jan; 37(1):95-105. PubMed ID: 30238401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
    N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.